Cargando…
Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795897/ https://www.ncbi.nlm.nih.gov/pubmed/33383838 http://dx.doi.org/10.3390/ijms22010263 |
_version_ | 1783634553041059840 |
---|---|
author | Śledziński, Paweł Nowak-Terpiłowska, Agnieszka Zeyland, Joanna |
author_facet | Śledziński, Paweł Nowak-Terpiłowska, Agnieszka Zeyland, Joanna |
author_sort | Śledziński, Paweł |
collection | PubMed |
description | Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid receptors being part of the endocannabinoid system present in animals. Over the years a growing body of scientific evidence has been gathered, suggesting that these compounds have therapeutic potential. In this article, we review the classification of cannabinoids, the molecular mechanisms of their interaction with animal cells as well as their potential application in the treatment of human diseases. Specifically, we focus on the research concerning the anticancer potential of cannabinoids in preclinical studies, their possible use in cancer treatment and palliative medicine, as well as their influence on the immune system. We also discuss their potential as therapeutic agents in infectious, autoimmune, and gastrointestinal inflammatory diseases. We postulate that the currently ongoing and future clinical trials should be accompanied by research focused on the cellular and molecular response to cannabinoids and Cannabis extracts, which will ultimately allow us to fully understand the mechanism, potency, and safety profile of cannabinoids as single agents and as complementary drugs. |
format | Online Article Text |
id | pubmed-7795897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77958972021-01-10 Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases Śledziński, Paweł Nowak-Terpiłowska, Agnieszka Zeyland, Joanna Int J Mol Sci Review Recently, there has been a growing interest in the medical applications of Cannabis plants. They owe their unique properties to a group of secondary metabolites known as phytocannabinoids, which are specific for this genus. Phytocannabinoids, and cannabinoids generally, can interact with cannabinoid receptors being part of the endocannabinoid system present in animals. Over the years a growing body of scientific evidence has been gathered, suggesting that these compounds have therapeutic potential. In this article, we review the classification of cannabinoids, the molecular mechanisms of their interaction with animal cells as well as their potential application in the treatment of human diseases. Specifically, we focus on the research concerning the anticancer potential of cannabinoids in preclinical studies, their possible use in cancer treatment and palliative medicine, as well as their influence on the immune system. We also discuss their potential as therapeutic agents in infectious, autoimmune, and gastrointestinal inflammatory diseases. We postulate that the currently ongoing and future clinical trials should be accompanied by research focused on the cellular and molecular response to cannabinoids and Cannabis extracts, which will ultimately allow us to fully understand the mechanism, potency, and safety profile of cannabinoids as single agents and as complementary drugs. MDPI 2020-12-29 /pmc/articles/PMC7795897/ /pubmed/33383838 http://dx.doi.org/10.3390/ijms22010263 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Śledziński, Paweł Nowak-Terpiłowska, Agnieszka Zeyland, Joanna Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title | Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title_full | Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title_fullStr | Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title_full_unstemmed | Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title_short | Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases |
title_sort | cannabinoids in medicine: cancer, immunity, and microbial diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795897/ https://www.ncbi.nlm.nih.gov/pubmed/33383838 http://dx.doi.org/10.3390/ijms22010263 |
work_keys_str_mv | AT sledzinskipaweł cannabinoidsinmedicinecancerimmunityandmicrobialdiseases AT nowakterpiłowskaagnieszka cannabinoidsinmedicinecancerimmunityandmicrobialdiseases AT zeylandjoanna cannabinoidsinmedicinecancerimmunityandmicrobialdiseases |